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Abstract
The Epstein-Barr virus (EBV) is an oncogenic human Herpes virus involved in the pathogenesis of nasal NK/T-cell lymphoma.
EBV encodes microRNAs (miRNAs) and induces changes in the host cellular miRNA profile. MiRNAs are short non-coding
RNAs of about 19–25 nt length that regulate gene expression by post-transcriptional mechanisms and are frequently
deregulated in human malignancies including cancer. The microRNA profiles of EBV-positive NK/T-cell lymphoma, non-
infected T-cell lymphoma and normal thymus were established by deep sequencing of small RNA libraries. The comparison
of the EBV-positive NK/T-cell vs. EBV-negative T-cell lymphoma revealed 15 up- und 16 down-regulated miRNAs. In contrast,
the majority of miRNAs was repressed in the lymphomas compared to normal tissue. We also identified 10 novel miRNAs
from known precursors and two so far unknown miRNAs. The sequencing results were confirmed for selected miRNAs by
quantitative Real-Time PCR (qRT-PCR). We show that the proinflammatory cytokine interleukin 1 alpha (IL1A) is a target for
miR-142-3p and the oncogenic BCL6 for miR-205. MiR-142-3p is down-regulated in the EBV-positive vs. EBV-negative
lymphomas. MiR-205 was undetectable in EBV-negative lymphoma and strongly down-regulated in EBV-positive NK/T-cell
lymphoma as compared to thymus. The targets were confirmed by reporter assays and by down-regulation of the proteins
by ectopic expression of the cognate miRNAs. Taken together, our findings demonstrate the relevance of deregulated
miRNAs for the post-transcriptional gene regulation in nasal NK/T-cell lymphomas.
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Introduction
The Epstein-Barr Virus (EBV) is an oncogenic human Herpes
virus that is involved in the pathogenesis of nasopharyngeal
carcinoma (NPC), stomach carcinoma and various tumours of B-
and T-cell origin such as Burkitt’s and Hodgkin’s lymphoma,
diffuse large B-cell lymphoma (DLBCL) and nasal NK/T-cell
lymphoma (for review, see [1]). Its oncogenic property is
highlighted by the ability of EBV to growth-transform B-
lymphocytes; these so-called lymphoblastoid cell lines (LCL’s) are
the in vitro correlate of B-cell lymphoproliferative disorders that
often arise under immunosuppression. In the various EBV-
associated tumour entities, the virus expresses different sets of
transformation-associated proteins as well as non-coding RNAs
[2]. These include the so-called EBER-RNAs, a snoRNA [3] and
a set of 25 miRNAs [4,5,6]. MiRNAs are short, 19–25 nt RNAs
with partial homology to sequences in their target mRNAs.
MiRNA genes are transcribed and processed in the nucleus, then
exported to the cytoplasm where they are further processed and
ultimately bound in most cases to the 39 untranslated region
(UTR) of their target mRNA by the RNA-induced-silencing-
complex (RISC). MiRNAs were also reported to bind to their
targets via 59UTR or open reading frame [7,8]. Association with
a target mRNA results in either translational repression or mRNA
degradation ultimately leading to reduced protein synthesis (for
review, see [9]). EBV not only expresses its own set of miRNAs but
also has a profound impact on the cellular miRNA profile in that
the overall level of cellular miRNAs appears to be down-regulated
in EBV-infected cells [10] and that the viral infection changes the
levels of specific miRNAs. For instance, various cellular miRNAs
are up- or down-regulated in NPC when compared to non-
infected tissue [11]. Among the EBV-associated tumours, NPC
and nasal NK/T-cell lymphoma are the two entities that are
virtually always infected with EBV. NK/T-cell lymphomas are
mainly found in South-east Asia where they constitute about 3–9%
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of all malignant lymphoma (Reviewed in [1]). The tumours mainly
arise in the nasal region but also in extranodal areas of the gastro-
intestinal tract, the skin, the liver or the spleen [12]. The tumours
grow very aggressively and are characterized by large necrotic
areas probably due to the secretion of large amounts of proteinases
[13]. Therefore, only small amounts of tumour tissue are available.
We nevertheless set out to determine the miRNA profiles of nasal
NK/T-cell lymphoma in comparison to non-EBV-infected T-cell
lymphoma using thymus as a non-transformed control tissue, by
utilizing the deep sequencing as a powerful tool. In addition to
establishing the miRNA profiles, we identified targets of the
deregulated cellular miRNAs.
Results
Analysis of the Small RNA Libraries
The miRNA profiles of EBV-positive nasal NK/T-cell lym-
phoma, EBV-negative T-cell lymphoma and non-transformed
thymus tissue were established as previously described [11]. In
brief, small RNA libraries were generated from pooled frozen
tissues and analysed by 454 deep-sequencing. The distribution of
reads obtained is schematically shown in Figure 1A. While the
major part represented miRNAs, we also obtained a background
of sequences derived from other RNAs such as rRNA, tRNA, sn/
snoRNAs, other ncRNAs or mRNA transcripts. In the thymus
small RNA library, 69% of the 46340 reads were identified as
miRNA sequences, the small RNA library from EBV-negative
lymphoma yielded 86% miRNA sequences from 35437 reads
while EBV-positive NK/T-cell lymphoma library showed a re-
duced amount of 53% of miRNA-derived sequences among 81889
reads. Of the known human miRNAs, we identified 348 in the
thymus library, 325 in the library from the EBV-positive but only
275 in the library of the EBV-negative T-cell lymphoma. The
library of the EBV-positive lymphoma contained the additional 36
viral miRNAs as outlined in Figure 1B.
Expression of Viral miRNAs in EBV-associated NK/T-cell
Lymphomas
Of note, we did not observe any EBV-miRNAs encoded by the
BHRF1 cluster (see Table S1) in accordance with previous results
showing that these miRNAs are only found in cells that harbor the
virus in a type III latency, such as a PTLD arising under
immunosuppression [14] but not, for instance, in NPC or stomach
carcinoma [11,15]. In contrast to the situation in NPC, where the
EBV miRNAs accounted for 5–19% of the total miRNAs, the viral
miRNAs in NK/T-cell lymphoma represented only 2.3% of the
total miRNAs. The five most expressed EBV-miRNAs BART7,
BART5, BART11-5p, BART1-5p and BART19-3p accounted for
,50% of the viral encoded and for ,1% of the total miRNAs. To
confirm the absence of the EBV-encoded miRNAs from the
BHRF1 cluster, the EBV-positive NK/T-cell lines HANKI and
NK-YS (latency type II) were analysed by northern blotting. As
shown in supporting Figure S1 A, neither the EBV-positive cells
nor the EBV-negative control cells NK92 or SUP-T1 expressed
any of the BHRF1 miRNAs, while the EBV-positive B95.8 cells
(which are in type III latency) clearly showed a signal.
Deregulated miRNAs in EBV-positive NK/T-cell and EBV-
negative T-cell Lymphomas Relative to Normal Tissue
We then compared the miRNA expression levels between the
different small RNA libraries. For this analysis, we set a threshold
of a 2-fold difference in expression and a representation of 0.1% in
both small RNA libraries. First, we looked at the miRNA
expression changes between the lymphomas and the normal
tissue. In EBV-negative T-cell lymphoma we could detect an up-
regulation for 14 miRNAs whereas 31 of the 45 deregulated
miRNAs were repressed relative to thymus (supporting Table S2).
For the EBV-positive lymphomas 18 miRNAs were induced while
28 of the 46 deregulated miRNAs showed a reduced expression
(supporting Table S3). Interestingly, most of the up-regulated
miRNAs in EBV-negative lymphoma were also induced in EBV-
positive lymphoma compared to normal tissue. For example, miR-
21 and miR-155 were among the four strongest induced miRNAs
in both lymphomas. The miRNAs with a reduced expression in
lymphoma relative to normal tissue only coincided partially e.g.
for miR-218 and miR-200 family. Ten miRNAs that were present
in the EBV-positive samples and thymus were not or almost un-
detectable in the EBV-negative tumours (Table 1). Of note, miR-
449a and miR-449b were also not present in thymus. The other
nine miRNAs, mainly members of the miR-200 family, showed
reduced levels or comparable expression in the EBV-positive
lymphomas as compared to thymus.
Differentially Expressed miRNAs in EBV-positive NK/T-cell
vs. EBV-negative T-cell Lymphomas
Furthermore, we compared the relative expression levels of the
cellular miRNAs between EBV-positive and EBV–negative lym-
phomas. In the EBV-positive NK/T-cell lymphomas, 15 cellular
miRNAs were up-regulated and 16 miRNAs were down-regulated
relative to the EBV-negative ones. For the miRNAs shown in the
diagram of Figure 1C, the level seen in thymus tissue was set to 1.
The strongest relative inductionwas observed formiR-145 (11-fold),
miR-143 (8-fold), and miR-125b (7-fold), while strongest reduction
was determined for miR-20b (10-fold), miR-181b (8-fold), andmiR-
146a+b (5-fold). MiR-145, -1280, -30a, -29b, 590-3p and let-7b of
the up-regulatedmiRNAs in the EBV-positive lymphomaswere also
induced relative to thymus. Otherwise, the expression of the most
down-regulated miRNAs was reduced relative to the EBV-negative
lymphoma as well as to normal tissue. Only miR-652, -20a, -19a, -
142-3p and miR-146a+b-5p were down-regulated compared to
EBV-negative lymphoma but showed no reduction in normal tissue.
MiR-590-3p and miR-142-5p were the only miRNAs which were
deregulated in EBV-positive lymphomas and at the same time
induced in both types of lymphomas compared to normal tissue.
As pointed out, we compared only those miRNAs that were
represented at least 0.1% in one of the libraries. The results for all
miRNAs detected by sequencing in the three libraries are shown in
Table S4.
Identification of New Cellular miRNAs
The analysis of the three small RNA libraries revealed 10 novel
star miRNA sequences derived from previously described miRNA
precursors (Table 2). Of these, five were only detected in the small
RNA library of the EBV-negative lymphoma, one was only
present in the EBV-positive lymphoma and one was only
detectable in thymus. We also detected three novel miRNA
sequences in the small RNA analysis of the EBV-negative
lymphoma shown in supporting Table S5. While this work was
in progress, the miRNA denoted miR pot.42 in supporting Table
S5 was deposited in miRBase as hsa-mir-3157 [16]. The table also
lists the chromosomal location of the three sequences. The
sequences were found in the human genome and also in other
hominid apes as well. Also, the predicted precursor folded into
a hairpin structure fitting all criteria for a true miRNA. We
therefore PCR-amplified the three sequences including 150 nt of
the 59- and 39-flanking regions; expression of the clones and
subsequent northern blotting showed expression of precursors and
the mature miRNAs of the expected size. However, northern blot
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analysis of the NK/T-cell lines did not yield any signal for the
endogenous miRNA (supporting Figure S1B).
Validation of miRNA Expression by Quantitative Real-
time PCR
We next tried to confirm the sequencing data by qRT-PCR. As
outlined above, the nasal NK/T-cell lymphoma contain large
necrotic areas; thus only limited amounts of material were
available. We therefore could only analyse the levels of 4 up-
and 4 down-regulated miRNAs in the EBV-positive vs. -negative
cases by PCR. We compared the expression of miR-205, -200c, -
145, and -148a (up-regulated) as well as miR-424, -142-3p, -181b,
and -20b (down-regulated). Figure 2 shows the results of the
quantitative Real-Time PCR for the comparison between EBV-
positive lymphoma and thymus (Figure 2A), EBV-negative and
thymus (Figure 2B) as well as EBV-positive and -negative
lymphoma (Figure 2C). For the lymphoma vs. thymus there were
two miRNAs which showed a different expression change by PCR
when compared to the sequencing results. For EBV-positive
lymphoma vs. thymus, miR-200c and miR-148a were reduced
whereas sequencing showed the same (miR-200c) or a slightly
stronger (miR-148a) expression in thymus. For the EBV-negative
lymphomas vs. thymus we found a reduced expression of miR-
142-3p and miR-20b by PCR but a slight up-regulation in the
lymphomas by sequencing.
When we compared the EBV-positive vs. EBV-negative
lymphoma, all miRNAs but miR-424 were up- or down-regulated
as measured by sequencing (see Figure 2C). By sequencing, miR-
424 was down-regulated in EBV-positive vs. negative lymphomas
and also down-regulated in both entities relative to thymus tissue
but was found induced in EBV-positive vs. -negative lymphomas
by PCR. The relative down-regulation of miR-424 for both
lymphoma entities vs. thymus was confirmed, though. For all other
miRNAs at least the same tendency of expression changes was
detectable by PCR and by sequencing. Note that miR-205 was not
detectable in the library of the EBV-negative lymphoma by
sequencing; therefore, no relative values that compare the EBV-
negative samples to the thymus and to the EBV-positive
lymphomas can be displayed as log2. Nevertheless, the relative
quantification of this miRNA by qRT-PCR confirmed the
repression of miR-205 in EBV-negative lymphoma compared to
thymus and the induction of the miRNA in EBV-positive ones.
We next analysed by qRT-PCR the relative expression levels of
deregulated miRNAs in the NK/T-cell lines SNT6 and SNK16,
one further case of nasal NK/T-cell lymphoma where frozen
tissue was available and three additional cases of nasal NK/T-cell
lymphoma where only paraffin-embedded material was available.
These were either compared with primary thymus tissue or
CD56+ cells isolated from healthy donors. It is assumed that
CD56+/CD3+ cells are the precursor cells for EBV-positive NK/
T-cell lymphoma [17]. When compared to primary thymus tissue,
the tested miRNAs miR-142-3p, -145, -181b, -200c, -205 and –
424 all were down-regulated in the tumor tissues and the cell lines
tested, with the exception of miR-181b and miR-424 that
essentially showed no change in the primary, frozen tissue of the
NK/T-cell lymphoma. This is shown in supplementary Figure S3
and further confirms the original observations obtained by
sequencing (see supporting Table S3). The comparison of
CD56+ primary cells isolated from peripheral blood yielded
essentially the same results with the exception of miR-205. Here,
the tumor tissues expressed elevated levels of this miRNA. This is
shown in supporting Figure S4. The sequence analysis had shown
a five-fold down-regulation of miR-205 in Thymus tissue as
compared to EBV+-NK/T-cell lymphoma while the non-infected
T-cell lymphoma showed no expression of this miRNA (Table 1).
Identification of the Pro-inflammatory Cytokine IL1A as
a Target of the Deregulated miR-142-3p
We then went on to identify potential targets for the deregulated
cellular miRNAs. A previous study had determined the mRNA
expression profile of EBV-infected nasal NK/T-cell lymphoma
lines and found, among others, the IL1A, BCL6, CD44 and c-
FOS genes to be induced and the interleukin 1 receptor 1 (IL1R1)
gene to be repressed compared to normal lymphocytes [18]. By
applying a combination of various prediction algorithms, we
identified the 39-UTR of c-FOS as a potential target for miR-181a
and miR-181b (down-regulated the in EBV-associated lympho-
mas), CD44 as a potential target of miR-20a and miR-106a, and
the IL1R1 as a target of miR-205 and -125a. When we tested the
39-UTRs of these genes in a luciferase reporter assay with the
respective miRNAs, we did not observe an effect of any of these
miRNAs on the reporter constructs (data not shown). Expression
Figure 1. Expression of small ncRNAs in the analysed small RNA libraries. A: Proportions of ncRNAs and transcripts detected by deep
sequencing of Thymus (total reads: 46340), EBV-negative T-cell (total reads: 35437), and EBV-associated NK/T-cell lymphoma (total reads: 81889). The
relative abundance is calculated as a quotient of the absolute number of a single class of RNA and the total number of all detected sequences in the
library. miRNA =microRNA; ncRNA = non-coding RNA; snRNA = small nuclear RNA; snoRNA = small nucleolar RNA; tRNA= transfer RNA;
rRNA= ribsomal RNA B: Expression of EBV-encoded miRNAs in EBV-associated NK/T-cell lymphoma. Relative distribution of viral miRNAs represented
as the percentage of the total EBV-encoded miRNA reads. No sequences were detected for miRNAs from the BHRF1-cluster C: Relative expression of
deregulated miRNAs in EBV-positive NK/T-cell vs. EBV-negative T-cell lymphoma. The left diagram shows the up-regulated miRNAs whereas the right
one represents the down-regulated miRNAs in EBV-associated NK/T-cell lymphomas. Presented is the relative miRNA expression as a percentage of
the total miRNA reads in the small RNA library after setting the thymus expression to 1. Only miRNAs with an at least two-fold difference in expression
and an expression of at least 0.1% are shown. The white bars represent the expression in EBV-negative T-cell lymphoma, the black ones the
expression in the EBV-positive NK/T-cell lymphoma.
doi:10.1371/journal.pone.0042193.g001
Table 1. Induced miRNAs showing no or only weak
expression in EBV-negative T-cell lymphoma.
miRNA relative expression [%]
Thymus EBV- EBV+
hsa-miR-200a 0,26 0,00 0,09
hsa-miR-200b 2,17 0,00 1,18
hsa-miR-203 0,11 0,00 0,10
hsa-miR-204 0,12 0,00 0,07
hsa-miR-205 1,49 0,00 0,28
hsa-miR-429 0,15 0,00 0,07
hsa-miR-449a+449b 0,00 0,00 0,21
hsa-miR-141 0,36 0,01 0,21
hsa-miR-199b-5p 0,26 0,02 0,22
hsa-miR-200c 0,88 0,03 1,03
doi:10.1371/journal.pone.0042193.t001
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of the cloned miRNAs from the vector pSG5 is shown in
supporting Figure S2. We further identified the 39-UTR of the
IL1A gene as a potential target for miR-142-3p, miR-181a and
miR-181b which are repressed in EBV-associated lymphomas.
The luciferase reporter analysis showed that miR-142-3p but not
the other two miRNAs had a significant effect on the reporter. As
shown in Figure 3A, we determined a down-regulation of the
reporter construct by 31% (p= 4.3610–8). The seed sequence of
potential binding site for miR-142-3p on the IL1A 39-UTR (boxed
in Figure 3B) was then changed by site-directed mutagenesis. The
mutated reporter lost its responsiveness towards miR-142-3p
demonstrating that the IL1A 39-UTR is a bona fide target of this
miRNA (Figure 3C). We determined the relative levels of miR-
142-3p and IL1A in the EBV-positive vs. -negative lymphomas
and found an inverse relationship pointing at an effect of this
miRNA vis-a`-vis the IL1A 39-UTR (Figure 3D). When we tried to
express miR-142-3p in NK- or T-cell lines that were at our
disposal by electroporation employing various systems, we got only
a small percentage of transfected cells or a large number of
apoptotic cells. That precluded a direct analysis by Western
blotting or FACS analysis. We therefore transfected 293T cells
with a full length cDNA clone which also comprised the 39-UTR;
as can be seen in Figure 3E, the band corresponding to IL1A was
reduced to about 70% when miR-142-3p was co-expressed. We
then analysed the HaCaT cell line which is known to express
IL1A; transient expression of miR-142-3p also resulted in an
approx. 30% reduction of the endogenous IL1A (Figure 3F). We
analysed the effect of miR-142-3p on the amount of secreted IL1A
in HaCaT cells. As shown in Figure 3G, the amount of IL1A in
the supernatant of the miR-142-3p expressing cells was reduced by
about 15% which is statistically significant (p = 0.0007).
The Differentially Expressed miR-205 Targets the
Oncogene BCL6
The computational prediction of potential targets had indicated
that the 39-UTR of the BCL6 proto-oncogene might be a target
for miR-17, -106a, -106b, -181a, -181b, and -205. We generated
expression clones for these miRNAs, either as single expression
clones or within a miRNA cluster and tested these with the cloned
BCL6-39-UTR. As shown in Figure 4, the miRNAs had no effect
on the empty reporter vector (Figure 4A), and only co-expression
of miR-205 (Figure 4B) resulted in a significant down-regulation of
the BCL6-39-UTR reporter by approx. 22% (p= 0.001). The seed
sequence of potential binding site for miR-205 on the BCL6 39-
UTR (boxed Figure 4C) was then changed by site-directed
mutagenesis and assayed again with miR-205. The mutated
reporter lost its responsiveness demonstrating that the BCL6- 39-
UTR is a target of this miRNA (Figure 4D). To show that miR-
205 indeed reduces the protein level of BCL6, the EBV-negative
SUP-T1 T-cell line was transfected with miR-205 expression
plasmid and the level of BCL6 protein was determined by Western
blot. The densitometric analysis of the BCL6 signal indicated
a reduction of BCL6 protein by 30%. A representative blot is
shown in Figure 4E.
To further analyse the differential expression of BCL6 in nasal
NK/T-cell lymphoma vs. primary tissue, we compared the
expression levels of BCL6 in CD56+ cells derived from two
healthy donors with the mRNA levels in the EBV-positive cell lines
SNK6, SNT10 and NK-92. Here we found a slight increase for
the BCL6 mRNA in SNK6 while the other two cell lines expressed
less BCL6 mRNA. The data for these two donors are shown in
supporting Figures S5 and S6. The results are compatible with
a down-regulation of BCL6 due to an up-regulation of the miR-
205 which targets this mRNA. In summary, we identified two
targets of two deregulated miRNAs in the NK/T-cell lymphoma.
Discussion
To the best of our knowledge, this is the first miRNA profile of
EBV-positive NK/T-cell lymphoma, T-cell lymphoma and
normal thymus tissue established by deep sequencing of small
RNA libraries as NK/T-cell lymphomas are virtually always EBV-
positive [1]. Therefore, we used EBV-negative T-cell lymphoma
for comparison. Two previous publications described a miRNA
analysis of thymus tissue [19,20]. The paper by Liang et al. (2007)
used a PCR-based method to evaluate miRNA levels in various
normal human tissues including thymus [19]. In their analysis, as
in ours, miR-16 was one of the predominantly expressed miRNAs.
Using miR-16 for normalization, we compared the values for the
thymus tissues for those miRNAs that were deregulated in our
lymphomas. We found that their data matched ours for some but
not all miRNAs. The publication by Barad et al. (2004) used
a micro array analysis of five normal human tissues including
thymus and reported for thymus that miR-96, -182, -183 and -
200a showed the strongest expression of all miRNAs tested [20].
These miRNAs were present in the thymus small RNA library
analysed here but did not represent highly expressed miRNAs. We
Table 2. New miRNAs from known precursors identified from different small RNA libraries.
name sequence genomic location reads in libraries
Thymus EBV- EBV+
hsa-miR-874-5p CGGCCCCACGCACCAGGGT 5q31.2 1 4
hsa-miR-1248-3p TGCTAGCAGAGTACACACAAG 3q27.3 4
hsa-miR-153-2-5p GTCATTTTTGTGATGTTGCAGC 7q36.3 4
hsa-miR-98-3p CTATACAACTTACTACTTTC Xp11.22 1
hsa-miR-382-3p AATCATTCACGGACAACACTT 14q32.31 2
hsa-miR-511-3p AATGTGTAGCAAAAGACAG 10p12.33 10
hsa-miR-1277-5p TATATATATATATGTACGTAT 11q24 3
hsa-miR-1185-3p ATATACAGGGGGAGACTCTTAT 14q32.31 2
has-miR-107-5p AGCTTCTTTACAGTGTTGCCTTGT 10q23.31 3 1
hsa-miR-let-7c-3p CTGTACAACCTTCTAGCTTTCC 21q21.2 2
doi:10.1371/journal.pone.0042193.t002
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assume that the different methods used were responsible for the
observed discrepancies.
When this analysis was designed, the nature of the non-
neoplastic precursor cells of the NK/T-cell lymphoma was still
a matter of debate. We therefore chose to analyse thymus tissue as
a non-transformed control tissue [21] known to be involved in
NK/T-cell development [22]. It is assumed today that most NK/
T-cell lymphomas are derived from CD56+ NK cells or
occasionally from cytotoxic T-cells [17]. Recently, Ng et al.
(2011) analysed the miRNA levels of nasal NK/T-cell lymphoma
and a panel of NK/T-cell lines in comparison to CD56+ precursor
cells by an array-based technology. They observed a general
down-regulation of cellular miRNAs with only a few up-regulated
miRNAs of most miRNAs analysed [23]. Our data confirm these
results in that we observe a general repression of miRNA
expression as demonstrated by the reduced relative number of
miRNA counts in the library of the EBV+-NK/T-cell lymphoma
(Figure 1) in line with our previous analyses of such libraries
obtained for EBV-positive nasopharyngeal carcinoma (NPC) and
diffuse large B-cell lymphoma (DLBCL) [11,24]. Other publica-
tions have also described a global repression of miRNAs in
tumours and that this repression can enhance tumorigenesis
[25,26].
One of the miRNAs which showed a reduced expression in both
EBV-positive NK/T-cell lymphoma as well as the EBV-negative
T-cell lymphomas was miR-218. The repression of miR-218 was
already described for gastric carcinoma and shown to function as
an inhibitor of invasion and metastasis [27]. Furthermore, the
reduction of miR-218 was associated with strong activation of
NFkB which is also often seen in NK/T-cell lymphoma [28]. The
paper by Ng et al (2011) did not report a change in expression for
miR-218, though [23]. In the EBV-negative lymphomas, the
members of the miR-200 family were not expressed or showed
only a very low expression. For most of them, the expression was
also reduced in EBV-positive lymphomas compared to thymus;
only miR-200b and miR-141 were slightly above the two-fold
reduction. The repression of these miRNAs coincides with
publications showing that the down-regulation of miR-200 family
contributes to metastasis of tumour cells by targeting ZEB1/ZEB2
and increasing E-cadherin [29].
MiR-424 and -128a+b were significantly down-regulated in
both tumour entities as compared to thymus. The down-regulation
of miR-424 was essentially confirmed by qRT-PCR in the NK/T-
cell lines and tumor tissue (supporting Figure S4). We had
previously detected also a down-regulation of miR-424 in prostate
carcinoma [30]. MiR-424 was linked to breast cancer as it is part
of an oestrogen-responsive gene network in breast carcinoma cell
lines [31]. The down-regulation of miR-142-5p and miR-142-3p
in the EBV-positive NK/T-cell lymphomas as compared to the
EBV-negative lymphomas was also confirmed by the qRT-PCR
analysis including a comparison between CD56+ primary cells and
the NK/T-cell lines and the tumor tissues (supporting Figure S4).
Ng et al. also found a strong down-regulation of this miRNA [23].
A computational search yielded the mRNA of the interleukin 1
alpha (IL1A) gene as a potential target for this miRNA.
Concomitant with the decrease in miR142-3p, the mRNA levels
for IL1A were up-regulated in EBV-positive lymphomas and we
could indeed prove that the IL1A 39-UTR contains a binding site
for this miRNA. Accordingly, miR-142 negatively regulated
a reporter construct featuring the IL1A-39-UTR which lost its
responsiveness upon binding site mutation. Lastly, we could
demonstrate that miR-142, when ectopically expressed in a human
cell line, reduced the protein levels of IL1A and also reduced the
levels of secreted IL1A. The up-regulation of IL1A was previously
Figure 2. Validation of miRNA expression by quantitative Real-
Time PCR. Total RNA out of the different samples used for sequencing
was reverse transcribed and the expression of miRNAs was analysed in
a light cycler by quantitative Real-Time PCR. The relative quantification
was carried out by the 22DDct-method after measurement the amount
of 5.8sRNA in each sample. Represented are the comparisons between
(A) EBV-positive lymphomas and thymus, (B) EBV-negative lymphomas
and thymus as well as (C) EBV-associated and EBV-negative lymphomas.
The shaded bars represent the sequencing results and the filled bars
the PCR-results. Bars above the x-axis show induced miRNAs and the
bars below repressed miRNAs.
doi:10.1371/journal.pone.0042193.g002
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shown in EBV-positive NK/T-cell lymphomas along with mRNAs
of other genes thought to be involved in cell proliferation such as
BCL6 or ERBB4 [18]. The up-regulation of IL1A in the EBV-
positive as compared to the EBV-negative lymphomas might be
explained by the ability of the pro-inflammatory cytokine to act as
an auto- or paracrine growth factor and as an inhibitor of
apoptosis (for review, see [32]). Besides, this cytokine is known to
be induced yet in several tumours, e.g. in NPCs, and to have
tumour promoting activity [33]. Except for the direct regulation of
IL1A by miR-142-3p found in this study, the miRNA has also an
indirect influence on IL1A. It was already reported that AC9 is
regulated by miR-142-3p and that the inhibition of AC9 resulted
in a reduced amount of cAMP [34]. As cAMP in turn is able to
induce the amount of IL1A, miR-142-3p is able to influence IL1A
indirectly by regulating AC9, too [35]. We show that IL1A is
a target for miR-142-3p and that the down-regulation of this
miRNA might confer a selective advantage to the EBV-infected
cell by elevating IL1A levels.
As mentioned, the BCL6 mRNA was also up-regulated in NK/
T-cell lymphomas [18]. It should be pointed out that other studies
did not find a deregulation of either IL1A or BCL6 [23,36]. A
computational analysis indicated the BCL6-39-UTR as a potential
target amongst others for miR-205 which was found here to be
down-regulated in the EBV-positive NK/T-cell lymphomas and
the EBV-negative samples as compared to normal tissue. The co-
expression of miR-205 with a reporter construct featuring the
BCL6-39-UTR showed that this 39-UTR is a target for miR-205;
mutation of the binding site led to non-responsiveness of the
reporter. Furthermore, ectopic expression of miR-205 resulted in
down-regulation of the BCL6-protein level. BCL6 was originally
discovered in B-cell lymphomas due to chromosomal transloca-
tions or mutations affecting this gene [37]. More recently, BCL6
was also found to play a role in the development of T-cell
lymphomas [38,39]. The BCL6 oncogene is a transcriptional
repressor; e.g. it blocks the expression of the tumour suppressor
proteins PDCD2 and p53 [40,41] as well as the cell cycle inhibitor
p21kip [42]. Our data are compatible with the role of miR-205 in
repression of BCL6 in normal tissue as expression of miR-205 was
higher in thymus than in lymphoma tissues; in addition, miR-205
was virtually undetectable in EBV-negative lymphomas. However,
we found only a slight induction of BCL6 in the NK/T-cell line
SNK6, and a down-regulation in SNT10 and NK-92. This issue
needs to be clarified in further studies.
We also found an induction of several miRNAs that could
mostly be verified in primary tumours (see below). Of the cellular
microRNAs described by Ng et al. that were induced in the
tumors/cell lines [23], we also observed an up-regulation of miR-
155 and miR-378 in the tumors vs. normal tissue. The sequence
analysis demonstrated that miR-449a+b were the only miRNAs
that were exclusively present in the EBV-positive samples. This
miRNA was induced in endometrioid adenocarcinomas and
adrenal hyperplasia [43,44], but was also implicated in inhibition
of cell-cycle progression and induction of apoptosis [45]. The up-
regulation of miR-145 in EBV-associated NK/T-cell lymphoma
was rather surprising as this miRNA is considered to have tumour
suppressive functions [46]. However, a re-analysis by qRT-PCR
showed that miR-145 was down-regulated both in the NK/T-cell
lines and the tumor tissue tested (supporting Figures S4 and S5) in
line with a tumor-suppressive function for miR-145 (see, for
instance [47]).
Of the viral miRNAs, all but those derived from the BHRF1
cluster were detectable. MiRNAs derived from the BHRF1 cluster
of EBV were reported to repress the chemokine CXCL-11 in
DLBCL of immune-compromised patients with an EBV latency
type III [14]. In contrast, the lymphomas in our study were
derived from immune-competent, HIV negative patients. In
accordance with the patients’ immune status, the EBV-positive
nasal NK/T-cell lymphomas analysed in the present study did not
express LMP or EBNA2 corresponding to an EBV latency type I.
In addition, miRNAs derived from the BHRF1-cluster were not
found as the type I latency does not appear to support expression
of these transcripts. This observation matches the situation
described for NPC [11,48], gastric carcinoma [15] and peripheral
T-cell lymphoma [49]. The absence of these miRNAs was also
reported for an EBV-positive type I Burkitt’s lymphoma cell line
[6], but so far, no data were available for primary nasal NK/T-cell
lymphoma. Of note, the previously described EBV-miRNAs miR-
BART-21 and -22 were both present in the lymphoma samples
pointing at a role for these miRNAs for EBV function. We recently
published that the viral miRNAs constituted 5–19% of all
miRNAs in EBV-infected NPC with BART4 showing the
strongest expression [11]; in NK/T-cell lymphoma, the viral
miRNAs represented 2.3% of the total miRNA reads with BART-
7, -5, -11-5p, 1-5p and -19-3p accounting for 50% of the viral
miRNAs which amount to about 1% of the total miRNA.
A distinct advantage of the procedure employed here is that
there is a potential to identify novel miRNAs as compared to
a micro-array or a PCR-based analysis. Indeed, we were able to
identify 10 novel miRNAs from known precursors as well as three
so far unknown miRNA precursors. While writing this article,
miR-pot.42 was published as miR-3157 at miRBase. The analysis
of the potential precursors for the two remaining miRNAs using
the ‘‘mfold’’ program (http://bibiserv.techfak.uni-bielefeld.de/
rnahybrid) showed an alignment into the expected hairpin
structures. In addition, the two predicted miRNAs were conserved
between various vertebrate species, for instance in chimpanzee
and gorilla. According to previously set standards [50], the
sequencing, the alignment in hairpin structures and the inter-
species conservation establish the three sequences as novel
miRNAs. We only obtained 2 reads for each of the three potential
Figure 3. Regulation of IL1A by miR-142. A: A firefly luciferase reporter containing the 39UTR of IL1A was cotransfected with different miRNAs
predicted to target this 39UTR or a control vector. The diagram represents five independent experiments with standard error carried out in duplicates.
The luciferase activity of control transfected cells was set to 100%. B: Schematic overview about the predicted binding site of miR-142-3p in the 39UTR
of IL1A. The sequence in the 39UTR mutated by site-directed-mutagenesis is indicated. C: Influence of miR-142 on the luciferase activity of the empty
vector, the IL1A-39UTR containing reporter as well as the mutated 39UTR. The graph shows five independent experiments which were done in
duplicates. D: Relative expression change of miR-142-3p and IL1A between EBV-associated NK/T-cell and EBV-negative T-cell lymphomas analysed by
a quantitative Real-Time PCR presented as log2. Relative quantification was measured by analysing GAPDH and 5.8sRNA and calculated by the 22DDct
–method. The pool of miRNAs used for the construction of the cDNA libraries (4 each, see Materials and Methods section) was used for this analysis. E:
Influence of mR-142 on the expression level of a full length IL1A cDNA clone in 293T cells. Extracts of 293T cells transfected with the miRNA
expression vector or vector control were analysed by Western blotting with specific IL1A and ß-actin antibodies. The signals for ß-actin served as
a loading control. F: Effect of miR-142 on the endogenous IL1A protein expression. Lysates of transfected HaCaT cells were analysed in a Western blot
with IL1A- and ß-actin - specific antibodies. The signals for ß-actin served as a loading control. G: Influence of miR-142 on the secretion of IL1A. The
IL1A-levels of supernatants of HaCaT transfected with miR-142 or vector control cells were analysed by ELISA. The diagram represents the results from
three independent experiments carried out in duplicate.
doi:10.1371/journal.pone.0042193.g003
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miRNAs which is a sign of low abundance and explains the failure
to get a signal in the northern blot analysis of NK/T-cell
lymphoma lines.
In summary, we describe for the first time a comprehensive
miRNA analysis of EBV-positive NK/T-cell lymphomas by deep
sequencing and demonstrate the relevance of deregulated
miRNAs for the post-transcriptional gene regulation in these
lymphomas. Likewise, we present an analysis of the miRNA
expression in thymus tissue as well as in EBV-negative T-cell
lymphomas. These data will help to acquire a better understand-
ing of the processes underlying lymphoma development and may
help to design rational strategies for treatment, i.e. via antisense
methodologies or by reintroduction of miRNAs into tumour cells.
Materials and Methods
Patients and Immunohistochemistry
For the lymphoma samples used in this study diagnosis was
performed on paraffin embedded tissue according to the WHO
classification 2008. Corresponding snap frozen lymphoma tissue
samples where collected at the Institute of Surgical Pathology,
University Hospital of Zurich. Five immunocompetent patients
with EBV-negative T-cell and two with EBV-associated nasal
NK/T-cell lymphomas were included in the study. Care was taken
to insure that the tumor content was at least 60–70% in the
samples used to generate the libraries. The use of patient’s
material and the study was approved by the ethical committee of
the Canton of Zu¨rich, Zu¨rich, Switzerland (Reg.-Nr. StV2-2007).
Written consent was obtained from all patients for the use of
materials.
Immunohistochemical stainings and EBER in situ Hybridiza-
tion were performed on an automated stainer (Ventana, Medical
Systems, Tucson, AZ, USA), using the antibodies LMP (Clone
CS1-4; Cell Marque, Rocklin, USA/California), EBNA2 (Clone
PE2; Dako, Glostrup, Denmark) and Zebra (Clone BZ.1; Dako,
Glostrup, Denmark). EBV encoded small RNA (EBER) was
hybridized to the inform EBER probe cocktail and stained with
ISH iVIEW nitro blue Tetrazolium (Ventana Medical Systems,
Tucson AZ, USA).
Small RNA Cloning
The small RNA fraction from five EBV-negative T-cell
lymphomas, two EBV-associated NK/T-cell lymphomas and four
thymus tissues, respectively, were pooled and three small RNA
libraries were generated. Small RNA cloning, sequencing and
analysis was carried out exactly as described previously [11].
Sequence Annotation
The sequence data was analysed with the help of Excel
macros. The analysis was done semi-manually because poly-a-
signals disturbed the 454 sequencing resulting in ‘‘A’’-insertions.
For sequence analysis first the poly-a-tail as well as the adapter-
and barcode sequences had to be removed. The resulting reads
were compared to a miRNA-database comprised of all mature
known mature miRNA-sequences from miRBase v12.0. Because
we chose less stringency there were a lot of false negatives.
Therefore the resulting sequences were identified afterwards by
using the search function of the database miRBase. The leftover
non-miRNA sequences were then tried to be assigned to
a ncRNA-database consisting of rRNA, tRNA, snoRNA,
snRNA etc. retrieved from fRNAdb:Blast (http://www.ncrna.
org/frnadb/blast, http://gene.fudan.sh.cn/), sno/scaRNAbase
(snoRNAbase.nsf). The sequences which could still not be
identified by this comparison were aligned against human or
EBV encoded transcripts (accession umber AJ507799) by
blasting (NCBI Nucleotide Blast). The miRNA expression of
the different tissues was compared by relative miRNA
expression. The relative expression is the absolute read number
of a single miRNA normalized to the absolute number of all
expressed miRNAs in a small RNA library.
Identification of New miRNAs
With the help of the search function of miRBase v12.0 new
mature miRNAs from already known precursors could be
identified. The genomic regions of potentially new miRNAs with
150 nt flanks were retrieved from UCSC Genome Browser
(http://genome.ucsc.edu/) to fold the sequence to secondary
structures by RNAhybrid (http://bibiserv.techfak.uni-bielefeld.
de/rnahybrid). Only sequences that folded into hairpins and
where the hairpins were conserved in another species were
considered as potentially new miRNA sequences.
Cell Culture
SUP-T1 [51], Jijoye [52] and BL41-B95.8 [53] cells were
cultured in RPMI 1640 supplemented with 10% fetal calf serum
(FCS) and 0.1% antibiotics. HANK-1 [54] was grown in MEM/
RPMI1640 supplemented with 5% human plasma, 1xInsulin-
Transferrin-Selen-X-Supplement (Invitrogen), 0.1% antibiotics
and 100 U/ml IL-2. NK-YS [55] were cultured in IMDM with
10% FCS, 1% Kanamycin and 100 U/ml IL-2. NK-92 cells [56]
were grown in X-Vivo Medium supplemented with 5% human
plasma, 0.5% Penicillin/Streptomycin and 500 U/ml IL-2. The
cultivation of 293T and HaCaT cells was carried out in DMEM
with 10% FCS and 0.1% antibiotics [30]. HaCaT cells [57] were
obtained from S. Smola, Institut of Virology, University Hosptial
of the Saarland, Homburg, Germany, 293T cells were cultured as
described previously [30].
Isolation of CD56+ Cells
PBMCs were isolated from buffy coats (obtained from the
Blutspendezentrale Saar-Pfalz GmbH, Germany) by ficoll separa-
tion. CD56+ cells were isolated from PBMCs by positive selection
using human CD56 MicroBeads on a MACS separator (Miltenyi
Biotec, Bergisch Gladbach. Germany). Total RNA was isolated
from CD56+ cells using Trifast (Peqlab, Erlangen, Germany).
Figure 4. BCL6 is a target of miR-205. A: Effect of the analysed miRNAs on the empty vector. Cells co-transfected with the miRNA expression
vectors, vector control and the empty reporter vector ware tested in luciferase assays. The diagram represents five independent experiments carried
out in duplicate with the standard error indicated. The Renilla luciferase activity was used for normalization and firefly luciferase activity of control
transfected cells was set to 100%. B: Regulation of the luciferase activity of the reporter construct containing the BCL6 39UTR by several miRNAs
predicted to target the 39UTR. The bars represent four different experiments done in duplicate. C: Schematic overview of the predicted binding site of
miR-205 in the 39UTR of BCL6. The sequence in the 39UTR mutated by site-directed-mutagenesis is indicated. D: Influence or miR-205 on the luciferase
activity of the empty vector, the wt-39UTR and the mutated BCL6 39UTR. The diagram shows the results of four independent experiments carried out
in duplicate. E: Transfection of miR-205 reduces the BCL6 protein in SUP-T1 cells. SUP-T1 cells transfected with miR-205 or a vector control were
analysed in a Western blot with BCL6- and ß-actin- specific antibodies. The signals for ß-actin served as a loading control.
doi:10.1371/journal.pone.0042193.g004
MiRNA Profile of EBV-Positive NK/T-Cell Lymphoma
PLoS ONE | www.plosone.org 10 August 2012 | Volume 7 | Issue 8 | e42193
Northern Blot
Total RNA was isolated from Jijoye, BL41-B95.8, Hank-1, NK-
YS, NK-92 and SUP-T1 cells using Trifast (Peqlab, Erlangen,
Germany) according to the manufacturer’s protocol, separated on
a 12% urea-polyacrylamid gel and transferred to nylon membrane
Hybond N (Amersham, Mu¨nchen, Germany) for 30 minutes at
15V. The RNA was chemically cross-linked for 2 h at 55uC [58].
After hybridization with radioactive labeled antisense RNA probes
overnight, the blots were washed twice for 15 minutes with
56SSC, 1% SDS and twice for 15 minutes with 16SSC, 1% SDS.
The RNA Probes were generated with miRVana Probe construc-
tion kit (Ambion, Austin, USA) according to the manufacturer’s
instructions.
Reverse Transcription and Quantitative Real-time PCR
DNaseI treated RNA was first polyadenylated with the Poly-A-
tailing kit from Ambion (Austin, USA). After an isolation step with
Trifast (Peqlab, Erlangen, Germany) the RNA was reversed
transcribed using a Poly-(T)-adapter primer (59-GCGAGCACA-
GAATTAATACGACTCACTATAGG(T)12VN*-39) and the
SuperScriptTM III First strand synthesis system (Invitrogen,
Carlsbad, USA). Semi-quantitative RT-PCR was carried out with
the Light-Cycler 1.5 System. MiRNAs were amplified using the
LightCyclerH FastStart DNAMasterPLUS SYBR Green I Kit
(Roche Applied Science, Mannheim, Germany) and a reverse
primer (59-GCGAGCACAGAATTAATACGAC-39) as well as
miRNA specific forward primers (miR-200c: 59-TAA-
TACTGCCGGGTAATGATGGA-39, miR-205: 59-
TCCTTCATT CCACCGGAGTCTG-39, miR-145: 59-
GTCCAGTTTTCCCAGGAATCCCTAA-39, miR-148a: 59-
TCAGTGCACTACAGAACTTTGT-39, miR-142-3p: 59-
TGTAGTGTTTCCT ACTTTATGGA-39, miR-181b: 59-AA-
CATTCATTGCTGTCGGTGGGT-39, miR-424: 59-CAG-
CAGCAATTCATGTTTTGAA-39, miR-20b: 59-
CAAAGTGCTCATAGTGCAG GTAGAA-39). For relative
quantification 5.8sRNA was used (5.8sRNA: 59-
CTACGCCTGTCTGAGCGTCGCTT-39). The amplification
of IL1A (for: 59-GGTTGA GTTTAAGCCAATCCA-39, rev:
59-TGCTGACCTAGGCTTGATGA-39) and GAPDH (59-
GGTTGAGTTTAAGCCAATCCA-39, 59-GGTTGAGTT-
TAAGCCAATCCA -39) was carried out with the universal probe
library (Roche Applied Science, Mannheim, Germany). Relative
expressions were calculated according to 2(2DDcT
)- method [59].
Oligonucleotides and Plasmids
To test 39UTRs in luciferase-assays, the complete 39UTRs were
cloned in the modified vector pMIR-RNL described previously
[11]. The following primers were used for PCR-amplification of
the 39UTRs: 59IL1A 59-GACTAGTC-
TACTGGGTGTGCTTGGCA-39, 39IL1A 59-CGAGCTCCAT-
TATGGTCTGAT CAC-39, 39BCL6 59- CGGCTAGCGAATT-
CAGCCAAACCCTGTCTCCGG-39, 59BCL6 59-
GCTCTAGATTCCGTCACAAAAGCCAGCT-39. The muta-
tion of the miRNA binding site in the 39UTR was done with a site-
directed mutagenesis and the following primers: 59IL1A 59-
TAAGAGTGGAACCTGTCGACACATATAATGTTGTT-39,
39IL1A 59-ACAACATTATATGTGTC GACAGGTTC-
CACTCTTACA-39, 59BCL6 59-TTTAACCAAAGGGTCGA-
CAATATATGGCA GAGTTG-39, 39BCL6 59-CAACTCTGC-
CATATATTGTCGACCCTTTGGTTAAA-39.
For the expression of miR-205, the primers 59miR205-Eco
59GGAATTCCGGGTAGGAGTATTCAGGTCC-39 and
39miR205_Bam 59-CGGGATCCTCCCTCTGAAGAAG-
CACGCA-39 were used to amplify the genomic luus (416bp) that
were then inserted in the pSG5 expression vector [24]. Likewise,
miR-142 was amplified using the primers 59miR142_Eco 59-
GGAATTCGGGATCTTAGGAAGCCACA-39 and
39miR142_Bam 59-CGGGATCCATGGAGGGCCTTTCAGG-
CAT-39. For the expression of miRNAs miR-125a, -181a, -181b, -
106a, -106b, and 17, the following primer pairs were used: 59miR-
125a_EcoCGGAATTCTGGCTCTCAGAATGTCTC-39,
39miR-125a_Bam 59-CGGGATCCGCCATCGTGTGGGTCT-
CAA-39; 59miR-181a-Bam 59-GCGGATCCTGTGATGTG-
GAGGTTTGCC; 39miR-181a-Bgl 59-GCAGATCTAGT-
GAGCTTGTCCACACAG-39; 59miR-181b-Bam 59-
GCGGATCCCAACGCTGTCGGTGAGTT-39, 39miR-181b-
Bgl 59-CAGATCTGCATGGGTGCTGAGGTCCT; 59miR-
17Eco 59-GGGAATTCCGTGTCTAAATGGACCTC-39,
39miR-17-Bam 59-GGGATCCACAGCATTGCAACCGATCC-
CAA-39; 59miR-106a Eco 59-GCGAATTCGCTTAGACTCTG-
TAAGCC-39, 39miR-106a-Bam 59-GGGATCCTACGCT-
GAAATGCAAACCTGC-39; 59miR-106b Eco 59-
GCGAATTCTGGTAAGTGCCCAAATTGCTGG-39; 39miR-
106b Bam 59-GGATCCAGCACAGGATCTAGGACACATG-
39; 59potmiR-27 Eco 59-GCGAATTCTGGAGCTCATGAAGA-
GACCAAG-39, 39potmiR-27 Bgl 59-GGAAGATCTAGGA-
CAGTCTGTGTCCTCAG-39; 59potmiR-34 Eco 59-
GCGAATTCTGCTGTGTCAGAAAGGCTTCAC-39, 39pot-
miR-34 59-GCGGATCCTGGGCATTCTTTCATCCCATC-
39; 59 potmiR-42 Eco 59-GCGAATTCGTCTG-
TATTCTCTTCTGGC-39; 39potmiR-42 Bam 59-
GGATCCCTGCTTTGAGAGTTCCTGAGT-39. The expres-
sion from the corresponding pSG5 plasmids was analzed by
Northern blotting (shown in supplementary Figure S2).
Luciferase Assays
For luciferase assays, 200 ng of reporter and 800 ng of miRNA
expression plasmid were transfected 24 h after seeding 293T cells
in 24-well plates using Nanofectin (PAA, Co¨lbe, Germany)
following the manufacturer’s protocol. Luciferase activity was
measured 48 h after transfection using the dual luciferase reporter
assay (Promega, Mannheim, Germany). The pMIR dual-luciferase
reporter vector was described previously [24].
Western Blotting
HaCaT cells were transfected with 2 mg plasmid 24 h after
seeding 36105 cells in 6-well plates. The transfection was done
with Metafectene with a ratio 1:6 (DNA/Metafectene). 26106
SUP-T1 cells were transfected with a nucleofectorH (Lonza, Ko¨ln,
Germany) by using 2 mg DNA, the nucleofector solution V and
the program O-017. 293T cells were seeded in 6-well plates and
transfected 24 h later with 1,5 mg IL1A-full length cDNA and
1,5 mg pSG5/miRNA by using Nanofectin (PAA, Co¨lbe, Ger-
many). 48 h after transfection cells were lysed with sample buffer.
Extracted proteins (30 mg) were separated on a 12.5% poly-
acrylamide gel and transferred to a ProtranTM nitrocellulose
membrane (Roth, Karlsruhe, Germany). After blocking the
membrane with 5% milk in PBS, the membranes were incubated
with the following primary antibodies: anti-human-IL1A Clone
4414 (R&D Systems, Minneapolis, USA), anti-human BCL6 clone
N3 (Santa Cruz biotechnology, Santa Cruz, USA), and anti-
human ß-actin (Sigma, Mu¨nchen, Germany). The secondary anti-
mouse antibodies used in this study were coupled to horseradish
peroxidase.
ELISA
The supernatant of HaCaT cells transfected with 2 mg plasmid
24 h after seeding 36105 cells in 6-well plates was collected 48 h
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after transfection. The supernatants were stored at 280uC after
centrifugation for 10 min at 3000 rpm. The secreted IL1A was
detected by the human IL-1alpha/ILF1 Duo Kit (R&D Systems,
Minneapolis, USA) according to the manufacturer’s protocol. The
measurement was done with a multiplate reader Victor XTM
(Perkin Elmer, Rodgau, Germany) at wavelengths of 450 nm and
550 nm. The data analysis was carried out by the software
WorkOut 2.5 with the 4-Parameter method.
Supporting Information
Figure S1 Analysis of miRNA expression by Northern
Blot. A: Analysis of BHRF1-miRNAs in the EBV-positive NK/T-
cell lymphoma cell lines by Northern Blot. Total RNA was
separated in a polyacrylamid gel and transferred to a nylon
membrane. After chemical cross linking, the mature miRNAs were
detected with radioactively labelled RNA probes. RNA from
EBV-infected B-cell lines served as a positive control whereas
RNA from EBV-negative NK-92 and SUP-T1 served as negative
control. In the EBV-associated NK/T-cell lymphoma cell lines
NK-YS and HANK-1, no expression of the BHRF1-miRNAs
could be observed. B: Northern Blot analysis of the potential new
miRNAs in NK/T-cell lines. Total RNA from 293T cells
transfected with a miRNA expression construct served as a positive
control. The band representing the tRNA served as loading
control.
(TIF)
Figure S2 Expression control of generated miRNA
expression constructs. Expression of novel miRNAs was
analyzed in 293T cells transfected with the indicated miRNA
expression constructs. The tRNA served as loading control.
(JPG)
Figure S3 Comparison of miRNA levels in cell lines/
tumors vs. Thymus. The miRNA expression levels in one
additional primary case (‘‘NKTL St. Gallen’’), three additional
cases of NKTL were formalin–fixed paraffin-embedded (FFPE)
material was available, and the NKTL cell lines SNK6 and
SNK10 were compared to thymus tissue. The value obtained for
Thymus tissue was set to 1 and the relative change is indicated.
The graphs represent the mean values of three experiments
carried out in duplicate.
(JPG)
Figure S4 Comparison of miRNA levels in cell lines/
tumors vs. CD56+ primary cells. The same tissues and cell
lines as described in Figure S3 were used and compared to the
value obtained for pooled CD56+ cells isolated from 5 healthy
donors. The graphs represent the mean values of three experi-
ments carried out in duplicate.
(JPG)
Figure S5 Comparison of BCL6 mRNa levels in CD56+
vs NKTL tumor cell lines. The mRNA levels of the BCL6
gene in non-transformed CD56+ cells isolated from healthy donor
1 were compared with the NKTL lines SNK6, SNK10, and NK-
92. The graphs represent the mean values of three experiments
carried out in duplicate.
(JPG)
Figure S6 Comparison of BCL6 mRNa levels in CD56+
vs NKTL tumor cell lines. The mRNA levels of the BCL6
gene in non-transformed CD56+ cells isolated from healthy donor
2 were compared with the NKTL lines SNK6, SNK10, and NK-
92. The graphs represent the mean values of three experiments
carried out in duplicate.
(JPG)
Table S1 Absolute and relative EBV-miRNA expression
in NK/T- cell lymphoma by sequencing.
(DOC)
Table S2 Differentially expressed miRNAs in EBV-
negative T-cell lymphoma compared to Thymus.
(DOC)
Table S3 Differentially expressed miRNAs in EBV-
positive T-cell lymphoma compared to Thymus.
(DOC)
Table S4 Absolute and relative miRNA expression in
the small RNA libraries analysed by sequencing.
(DOC)
Table S5 New miRNAs from unknown precursors
identified from EBV-negative T-cell lymphoma.
(DOCX)
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